BENZODIAZEPINE AND OPIOID CONCURRENT THERAPY PRIOR AUTHORIZATION REQUEST FORM

OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328

Optum Rx®

United Healthcare Community Plan

Today's Date
☐☐ / ☐☐ / ☐☐☐☐

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be returned****

Patient's Medicaid # ☐☐☐☐☐☐☐☐☐☐☐☐	Date of Birth ☐☐ / ☐☐ / ☐☐☐☐
Patient's Name	Prescriber's Name
Prescriber's IN License # ☐☐☐☐☐☐☐☐	Specialty
Prescriber's NPI # ☐☐☐☐☐☐☐☐☐☐	Prescriber's Signature
Return Fax # ☐☐☐ - ☐☐☐ - ☐☐☐☐	Return Phone # ☐☐☐ - ☐☐☐ - ☐☐☐☐
Check box if requesting retro-active PA ☐	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

PA is required for the following:

- **Claim(s) for a new opioid(s) to be used concurrently with benzodiazepines and exceeding 7 days within a 180-day period**
- **Claim(s) for new benzodiazepine(s) to be used concurrently with opioids and exceeding 7 days of therapy within a 180-day period and/or exceeding established benzodiazepine/opioid concurrent therapy quantity limits (see Sedative Hypnotics Benzodiazepine PA criteria).**

Benzodiazepine Agent(s)	Prescriber Name	Quantity	Dosage Regimen/Duration

Opioid Agent(s)	Prescriber Name	Quantity	Dosage Regimen/Duration

***NOTE: If prescribers of the opioids and benzodiazepines are not the same, please answer the following questions:**

- Are you requesting PA for: ☐ Benzodiazepine Agent(s) ☐ Opioid Agent(s) ☐ Both
- Is/are the other prescriber(s) aware of the request for concurrent therapy? ☐ Yes ☐ No
- Has the other prescriber been consulted about the risk associated with concurrent therapy, and do all prescribers involved believe continuing with concurrent therapy is warranted, given the risks associated with concurrent use? ☐ Yes ☐ No

PA Requirements:

Member diagnosis(es) for use of benzodiazepine therapy:

_____

Prior therapies attempted for the above diagnosis(es):

Drug Therapy	Dosage Regimen	Dates of Utilization

Do you plan to continue benzodiazepine therapy for this member? □ Yes □ No

If no, please provide withdrawal plan:

_____

Member diagnosis(es) for use of opioid therapy:

_____

Prior therapies attempted for the above diagnosis(es):

Drug Therapy	Dosage Regimen	Dates of Utilization	Reason for Discontinuation

Do you plan to continue opioid therapy for this member? □ Yes □ No

If no, please provide withdrawal plan:

_____

Attestation:

I,_____, hereby attest to the following:
(Prescriber Name)

- **The member's INSPECT report has been evaluated and continues to be evaluated on a regular basis (per IC 35-48-7-11.1, DO NOT attach a copy of the INSPECT report to this PA request)**
- **I have educated the member in regards to the risks of concurrent utilization of benzodiazepine and opioid therapy, and the member accepts these risks**
- **If applicable, I have consulted other prescribers involved in concurrent therapy and all prescribers involved agree to pursue concurrent opioid and benzodiazepine therapy for this member**
- **I acknowledge, as the prescriber initiating or maintaining concurrent benzodiazepine and opioid therapy, the risk of adverse event(s), including respiratory depression, coma, and death, associated with concurrent utilization**

Prescriber Signature:_____

Prescriber signature is required for consideration. Electronic or stamped signature will not be accepted

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.